Decheng Capital LLC
An institutional investment manager in MENLO PARK, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 2010850.
- Reported value$731.7m
- Positions14
Holdings: 14 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| CG Oncology IncCGON | COM | 156944100 | 453 | 61.9% | 6,371,669 | Unchanged | |
| Nuvation Bio Inc.NUVB | COM | 67080N101 | 147 | 20.1% | 25,954,439 | Unchanged | |
| Aardvark Therapeutics IncAARD | COM | 002942100 | 22.6 | 3.1% | 3,917,299 | Unchanged | |
| Aclaris Therapeutics, Inc.ACRS | COM | 00461U105 | 21.4 | 2.9% | 4,041,736 | Unchanged | |
| Upstream Bio Inc.UPB | COM | 91678A107 | 18.9 | 2.6% | 2,724,868 | Unchanged | |
| Arcus Biosciences, IncRCUS | COM | 03969F109 | 14.3 | 2.0% | 464,779 | Reduced−13,040 | |
| Equillium Inc.EQ | COM | 29446K106 | 14.2 | 1.9% | 4,447,308 | Unchanged | |
| Revolution Medicines Inc(Nsm)RVMD | COM | 76155X100 | 9.9 | 1.3% | 52,667 | Reduced−40,833 | |
| Lyell Immunopharma, Inc. | COM | 55083R104 | 9.7 | 1.3% | 692,050 | Unchanged | |
| BeyondSpring Inc. | SHS | G10830100 | 6.7 | 0.9% | 3,800,702 | Unchanged | |
| Zentalis Pharmaceuticals Inc.ZNTL | COM | 98943L107 | 6.4 | 0.9% | 1,323,327 | Unchanged | |
| Newamsterdam Pharma Co NV | COM | N62509109 | 6.0 | 0.8% | 176,887 | Reduced−148,170 | |
| Pyxis Oncology, Inc (formerly Apexigen)PYXS | COM | 747324101 | 1.0 | 0.1% | 326,810 | Unchanged | |
| Tango Therapeutics IncTNGX | COM | 87583X109 | 0.6 | <0.1% | 20,000 | New+20,000 |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Krystal Biotech IncKRYS | COM | 501147102 | 0.0 | 0.0% | 0 | Sold out−7,300 |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-096837 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.